Effects of gonadotropin-releasing hormone agonist pretreatment on frozen embryo transfer outcomes in artificial cycles: a meta-analysis
Authors:
- 20 October 2022
- journal article
- review article
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 308 (3) , 675-683
Abstract
Purpose Gonadotropin-releasing hormone agonist (GnRHa) before artificial cycle (AC) is expected to improve pregnancy outcomes in frozen-thawed embryo transfer (FET). Many studies have explored the impact of GnRHa pretreatment of AC in FET, but the results were inconsistent. This meta-analysis was performed to systematically evaluate the effect of GnRHa pretreatment on AC in FET. Methods The last search was January 31, 2022. Randomized controlled trials and cohort studies aiming to assess the effect of GnRHa as the pretreatment of AC for endometrial preparation in FET were included. GnRHa was used before AC in the treatment group. In the control group, no pretreatment was used before AC. The eligible studies included at least one of the following outcomes: implantation, clinical pregnancy, and live birth. We calculated the odds ratio (OR) or mean difference (MD) and 95% confidence interval (CI) for each study and used a random-effects or fixed model to estimate the results. Results 27 articles (10 RCTs and 17 non-RCTs) and 14152 patients were included. AC + GnRHa improved the implantation rate (OR = 1.31, 95% CI 1.03–1.66, I2 = 79%), clinical pregnancy rate (OR = 1.27, 95% CI 1.10–1.45, I2 = 53%), and live birth rate (OR = 1.16, 95% CI 1.05–1.29, I2 = 39%). We also found that AC + GnRHa increased the implantation rate (OR = 1.35, 95% CI 1.07–1.69, I2 = 53%) and clinical pregnancy rate (OR = 1.50, 95% CI 1.12–2.01, I2 = 50%) in repeated implantation failure. In addition, AC + GnRHa was positively associated with preterm birth (OR = 1.5, 95% CI 1.15–1.94, I2 = 0%). Conclusions GnRHa pretreatment in FET can improve implantation, clinical pregnancy, and live birth rates, especially in patients with repeated implantation failure. GnRHa pretreatment seems to improve FET outcomes, though with a higher preterm birth rate.Keywords
This publication has 22 references indexed in Scilit:
- A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosisJournal of Ovarian Research, 2014
- Antiretroviral interventions for preventing breast milk transmission of HIVCochrane Database of Systematic Reviews, 2014
- Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trialsCochrane Database of Systematic Reviews, 2014
- Adenomyosis is a potential cause of recurrent implantation failure during IVF treatmentAustralian and New Zealand Journal of Obstetrics and Gynaecology, 2011
- Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trialsJournal of Clinical Epidemiology, 2010
- Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapyHuman Reproduction, 2009
- The incidence of aberrant endometrial αvβ3 vitronectin expression in a high risk infertility population: could prolonged GnRH agonist therapy play a role?Journal of Assisted Reproduction and Genetics, 2007
- Pituitary suppression in ultrasound-monitored frozen embryo replacement cycles. A randomised studyHuman Reproduction, 2004
- Dose-Dependent Effects of Gonadotropin Releasing Hormone on Matrix Metalloproteinase (MMP)-2, and MMP-9 and Tissue Specific Inhibitor of Metalloproteinases-1 Messenger Ribonucleic Acid Levels in Human Decidual Stromal Cellsin VitroThe Journal of Clinical Endocrinology & Metabolism, 2003
- Gonadotropin-Releasing Hormone Agonist (GnRH-a) Therapy Alters Activity of Plasminogen Activators, Matrix Metalloproteinases, and Their Inhibitors in Rat Models for Adhesion Formation and Endometriosis: Potential GnRH-a–Regulated Mechanisms Reducing Adhesion FormationFertility and Sterility, 1998